Clinical Trial: Superparamagnetic Iron Oxide for Sentinel Lymph Node Localization in Patients With Cutaneous Melanoma, a Randomized Phase III Multi-center Non- Inferiority Trial: MagMen-II

U.S., April 28 -- ClinicalTrials.gov registry received information related to the study (NCT07552597) titled 'Superparamagnetic Iron Oxide for Sentinel Lymph Node Localization in Patients With Cutaneous Melanoma, a Randomized Phase III Multi-center Non- Inferiority Trial: MagMen-II' on April 20.

Brief Summary: A randomized, international, phase III, multi-center, non- inferiority trial assessing the safety and efficacy of Magtrace(R) (superparamagnetic iron oxide, SPIO) in identification of lymph nodes in patients with cutaneous melanoma undergoing a sentinel lymph node biopsy (SLNB). Participants will be injected with both tracer methods Technetium (Tc99) plus Blue Dye (BD) and Magtrace(R)). They will undergo both a lymphoscintigraphy and...